The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.”
Tubed pumps deliver insulin via a tube connected to an infusion set. Tandem has turned its tubed Mobi pump into a tubeless design by replacing the infusion set with a disposable on-body kit. Users can choose to wear it as a tubed or tubeless pump.
Tandem plans to enter the tubeless pump market next year. The company committed to the launch window after receiving FDA clearance for a new infusion set and cartridge for Mobi, which is cleared for up to seven days of wear.
William Blair analysts expect “a relatively smooth transition to Mobi tubeless.” Tandem should see “little pausing of current Mobi new customer growth” because the core device remains the same, the analysts said in a note to investors. Patients interested in the new product can buy the tubed Mobi device and switch to the tubeless infusion set and cartridge when they come to market.
Patients could switch to Mobi tubeless from rival devices, Leerink analysts said. The analysts’ prediction reflects their belief that the device has “advantages in form factor and pharmacy access.” Patients who currently rely on multiple daily injections to manage their diabetes may also switch to Mobi tubeless, the analysts said.
Tandem plans a limited launch before expanding to full commercial availability in the first half of next year, William Blair analysts said. The rollout will allow the company to build manufacturing capacity and update pharmacy contracts.
Source link







